Shares of Sage Therapeutics were exploding in Tuesday trading after the Food and Drug Administration gave the ‘ok’ to expediting development of the company’s drug, SAGE-217, to treat major depressive disorder and postpartum depression. Shares were up as much as 15% after the company announced the news. It was in February that the drug had … Continue reading “Sage Shares Soar After FDA Gives Green Light for This”
Tag: sage-217
Biotech & Pharma
Sage Therapeutics Shares Skyrocket on Positive Depression Drug Trial Results
Shares of Sage Therapeutics were climbing fast on Thursday after the company announced positive mid-stage…
December 7, 2017